[go: up one dir, main page]

WO1998001159A3 - Composition for enhanced uptake of polar drugs from mucosal surfaces - Google Patents

Composition for enhanced uptake of polar drugs from mucosal surfaces Download PDF

Info

Publication number
WO1998001159A3
WO1998001159A3 PCT/GB1997/001852 GB9701852W WO9801159A3 WO 1998001159 A3 WO1998001159 A3 WO 1998001159A3 GB 9701852 W GB9701852 W GB 9701852W WO 9801159 A3 WO9801159 A3 WO 9801159A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
mucosal surfaces
enhanced uptake
polar drugs
metabolisable
Prior art date
Application number
PCT/GB1997/001852
Other languages
French (fr)
Other versions
WO1998001159A2 (en
Inventor
Lisbeth Illum
Peter James Watts
Original Assignee
Danbiosyst Uk
Lisbeth Illum
Peter James Watts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst Uk, Lisbeth Illum, Peter James Watts filed Critical Danbiosyst Uk
Priority to GB9900050A priority Critical patent/GB2330533B/en
Priority to AU34539/97A priority patent/AU722724B2/en
Priority to JP10504949A priority patent/JP2000515503A/en
Priority to EP97930663A priority patent/EP0993305A2/en
Publication of WO1998001159A2 publication Critical patent/WO1998001159A2/en
Publication of WO1998001159A3 publication Critical patent/WO1998001159A3/en
Priority to NO985956A priority patent/NO985956L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

A composition for administration to a mucosal surface of a mammal comprising a non-metabolisable bile salt analogue and a therapeutic agent. Preferably the non-metabolisable bile salt analogue is a non-naturally occurring conjugate of cholic acid and an amino acid, and in particular cholylsarcosine. Preferably the therapeutic agent is a polar molecule.
PCT/GB1997/001852 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces WO1998001159A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB9900050A GB2330533B (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces
AU34539/97A AU722724B2 (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces
JP10504949A JP2000515503A (en) 1996-07-06 1997-07-07 Compositions for enhancing uptake of polar drugs from mucosal surfaces
EP97930663A EP0993305A2 (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces
NO985956A NO985956L (en) 1996-07-06 1998-12-18 Mixture for improved uptake of polar drugs from mucosal surfaces

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9614235.1 1996-07-06
GBGB9614235.1A GB9614235D0 (en) 1996-07-06 1996-07-06 Composition for enhanced uptake of polar drugs from mucosal surfaces

Publications (2)

Publication Number Publication Date
WO1998001159A2 WO1998001159A2 (en) 1998-01-15
WO1998001159A3 true WO1998001159A3 (en) 1998-03-26

Family

ID=10796483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/001852 WO1998001159A2 (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces

Country Status (8)

Country Link
EP (1) EP0993305A2 (en)
JP (1) JP2000515503A (en)
KR (1) KR20000023583A (en)
AU (1) AU722724B2 (en)
CA (1) CA2257563A1 (en)
GB (2) GB9614235D0 (en)
NO (1) NO985956L (en)
WO (1) WO1998001159A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
AU2681300A (en) * 1999-02-22 2000-09-14 Elan Corporation, Plc Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2004052405A1 (en) * 2002-12-11 2004-06-24 Chong Kun Dang Pharmaceutical Corp. Oral formulations for poorly absorptive hydrophilic drugs
DE102004027924A1 (en) * 2004-06-09 2005-12-29 Röhm GmbH & Co. KG Pharmaceutical form containing the active ingredient cholylsarcosine
MX2008012678A (en) 2006-04-07 2008-12-17 Merrion Res Iii Ltd Solid oral dosage form containing an enhancer.
CN102046192B (en) 2008-05-07 2014-11-19 默里昂研究Ⅲ有限公司 Composition and preparation method of GnRH-related compounds
ES2929471T3 (en) 2009-06-18 2022-11-29 Acerus Pharmaceuticals Usa Llc Safe administration of desmopressin
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
BR112013017169A2 (en) 2011-01-07 2016-10-04 Merrion Res Iii Ltd iron pharmaceutical compositions for oral administration
CN107205948B (en) 2015-01-29 2021-12-14 诺和诺德股份有限公司 Tablets containing GLP-1 agonist and enteric coating
CN108201531A (en) * 2016-12-19 2018-06-26 湖南尔康湘药制药有限公司 Segmented intestine targeted starch capsule of highly dissoluble sulbenicillin sodium and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007923A1 (en) * 1989-01-19 1990-07-26 California Biotechnology Inc. Transmembrane formulations for drug administration
DE4222647A1 (en) * 1991-07-15 1993-01-21 Sandoz Ag PEPTIDE PREPARATIONS
WO1995001183A1 (en) * 1993-06-29 1995-01-12 Ferring B.V. Compositions for nasal administration of desmopressin
WO1997006813A1 (en) * 1995-08-15 1997-02-27 Asahi Kasei Kogyo Kabushiki Kaisha Mucosal preparation containing physiologically active peptide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007923A1 (en) * 1989-01-19 1990-07-26 California Biotechnology Inc. Transmembrane formulations for drug administration
DE4222647A1 (en) * 1991-07-15 1993-01-21 Sandoz Ag PEPTIDE PREPARATIONS
WO1995001183A1 (en) * 1993-06-29 1995-01-12 Ferring B.V. Compositions for nasal administration of desmopressin
WO1997006813A1 (en) * 1995-08-15 1997-02-27 Asahi Kasei Kogyo Kabushiki Kaisha Mucosal preparation containing physiologically active peptide

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
AUNGST, BRUCE J. ET AL: "Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter", J. PHARMACOL. EXP. THER. (1988), 244(1), 23-8 CODEN: JPETAB;ISSN: 0022-3565, 1988, XP002049338 *
BIOCHEM. PHARMACOL. (1983), 32(5), 773-6 CODEN: BCPCA6;ISSN: 0006-2952, 1983 *
CHEMICAL ABSTRACTS, vol. 112, no. 6, 5 February 1990, Columbus, Ohio, US; abstract no. 42406, NAGAI, T. ET AL: "Absorption of fibroblast interferon -.beta. in powder dosage form from nasal mucosa in rabbits" XP002049341 *
CHEMICAL ABSTRACTS, vol. 95, no. 13, 28 September 1981, Columbus, Ohio, US; abstract no. 109081, ZIV, EHUD ET AL: "Bile salts promote the absorption of insulin from the rat colon" XP002049343 *
CHEMICAL ABSTRACTS, vol. 98, no. 23, 6 June 1983, Columbus, Ohio, US; abstract no. 191258, ZIV, E. ET AL: "Bile salts facilitate the absorption of heparin from the intestine" XP002049342 *
CONGR. INT. TECHNOL. PHARM., 5TH (1989), VOLUME 1, 91-8 PUBLISHER: ASSOC. PHARM. GALENIQUE IND., CHATENAY MALABRY, FR. CODEN: 56SEA5, 1989 *
GORDON, G. S. ET AL: "Nasal absorption of insulin: enhancement by hydrophobic bile salts", PROC. NATL. ACAD. SCI. U. S. A. (1985), 82(21), 7419-23 CODEN: PNASA6;ISSN: 0027-8424, 1985, XP002049334 *
KRAMER W ET AL: "MODIFIED BILE ACIDS AS CARRIERS FOR PEPTIDES AND DRUGS", JOURNAL OF CONTROLLED RELEASE, vol. 46, no. 1/02, 5 May 1997 (1997-05-05), pages 17 - 30, XP000680749 *
LIFE SCI. (1981), 29(8), 803-9 CODEN: LIFSAK;ISSN: 0024-3205, 1981 *
LONGENECKER, JOHN P. ET AL: "Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep", J. PHARM. SCI. (1987), 76(5), 351-5 CODEN: JPMSAE;ISSN: 0022-3549, 1987, XP002049340 *
NAKADA, YUICHIRO ET AL: "The effect of additives on the oral mucosal absorption of human calcitonin in rats", J. PHARMACOBIO-DYN. (1988), 11(6), 395-401 CODEN: JOPHDQ;ISSN: 0386-846X, 1988, XP002049337 *
NAKADA, YUICHIRO ET AL: "The effect of bile salts on the oral mucosal absorption of human calcitonin in rats", J. PHARMACOBIO-DYN. (1989), 12(12), 736-43 CODEN: JOPHDQ;ISSN: 0386-846X, 1989, XP002049336 *
SCOTT-MONCRIEFF, J. CATHARINE ET AL: "Enhancement of Intestinal Insulin Absorption by Bile Salt Fatty Acid Mixed Micelles in Dogs", J. PHARM. SCI. (1994), 83(10), 1465-9 CODEN: JPMSAE;ISSN: 0022-3549, 1994, XP002049335 *
UCHIDA, NAOKI ET AL: "Influence of bile salts on the permeability of insulin through the nasal mucosa of rabbits in comparison with dextran derivatives", INT. J. PHARM. (1991), 74(2-3), 95-103 CODEN: IJPHDE;ISSN: 0378-5173, 1991, XP002049339 *

Also Published As

Publication number Publication date
GB9900050D0 (en) 1999-02-24
GB2330533A (en) 1999-04-28
AU3453997A (en) 1998-02-02
GB9614235D0 (en) 1996-09-04
CA2257563A1 (en) 1998-01-15
NO985956D0 (en) 1998-12-18
EP0993305A2 (en) 2000-04-19
JP2000515503A (en) 2000-11-21
NO985956L (en) 1998-12-18
WO1998001159A2 (en) 1998-01-15
GB2330533B (en) 2000-10-25
AU722724B2 (en) 2000-08-10
KR20000023583A (en) 2000-04-25

Similar Documents

Publication Publication Date Title
WO1998001159A3 (en) Composition for enhanced uptake of polar drugs from mucosal surfaces
CA2304958A1 (en) Bioadhesive compositions and methods for topical administration of active agents
EP2016950A8 (en) Pharmaceutical composition comprising an exendin-4 peptide
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
WO1997049736A3 (en) Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
WO1996040086A3 (en) Compositions and methods for topical administration of pharmaceutically active agents
HUP0004439A3 (en) 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
WO2000033825A3 (en) Compositions and methods for amelioration of human female sexual dysfunction
BG104245A (en) Plasma protein-containing pharmaceutical compositions
AU3435497A (en) Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies
EP0354992A3 (en) Conjugates of VIP and active fragments thereof with hydrophobic moieties and topical compositions for use in the treatment of male impotence
AU2001264515A1 (en) Melphalan derivatives and their use as cancer chemotherapeutic drugs
CA2268455A1 (en) Methods and apparatus for treatment of parkinson's disease
CA2278422A1 (en) D-methadone, a nonopioid analgesic
CA2202397A1 (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
WO2001054706A3 (en) Method for treating kidney disorders
AU3771697A (en) Amino acid compositions and use thereof in immunosuppression
WO2002058589A3 (en) Agents and methods for promoting bone growth
RU99103692A (en) AMINO ACID COMPOSITIONS AND THEIR APPLICATION IN IMMUNO DEPRESSION
CA2189145A1 (en) Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent
AU2921999A (en) Indole-2,3-dione-3-oxime derivatives for therapeutic use
CA2420640A1 (en) Combination preparations of 3-n-formyl hydroxy amino propyl phosphonic acid derivatives or 3-n-acetyl hydroxy amino propyl phosphonic acid derivatives together with special pharmaceutical active ingredients
AU2187197A (en) Transdermally administered acetylcysteine as mucolytic agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA GB JP KR NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA GB JP KR NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2257563

Country of ref document: CA

Ref country code: CA

Ref document number: 2257563

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: GB

Ref document number: 9900050

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997930663

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019997000028

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 09214527

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997930663

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997000028

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997930663

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997000028

Country of ref document: KR